Skip to content
Review Open access

Biomarkers and Polysomnographic Parameters in Obstructive Sleep Apnea and OSA with Comorbidities: A Narrative Review

Sep 2026 · International Journal of Innovative Science and Research Technology · 0 citations

TL;DR

This review synthesizes the rationale for and evidence behind a set of low-cost, routinely available blood-derived biomarkers — serum uric acid, fibrinogen, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and the systemic inflammatory response index — as candidate correlates of polysomnographic severity in OSA.

Abstract

Obstructive sleep apnea (OSA) is a highly prevalent sleep-related breathing disorder that drives substantial cardiovascular, metabolic, and cerebrovascular morbidity through recurrent cycles of intermittent hypoxia, sleep fragmentation, oxidative stress, and systemic inflammation. Globally, OSA affects close to one billion adults, with roughly 425 million living with moderate-to-severe disease; prevalence estimates in India range from 3.7% to 21%, with about 5% of adults affected at a moderate-to-severe level. Despite this burden, the apnea-hypopnea index (AHI) — the mechanical, frequency-based metric that anchors current diagnostic and severity classification — correlates poorly with individual comorbidity risk and symptom burden, as it disregards event duration, desaturation depth, sleep-stage distribution, and cumulative hypoxic load. Major sleep and cardiovascular society guidelines have not yet incorporated inflammatory or REM-specific biomarkers into diagnostic or prognostic frameworks, even though expert consensus repeatedly flags this as an unmet need. This review synthesizes the rationale for and evidence behind a set of low-cost, routinely available blood-derived biomarkers — serum uric acid, fibrinogen, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and the systemic inflammatory response index (SIRI) — as candidate correlates of polysomnographic severity in OSA, with particular attention to REM-specific indices and to patients with OSA-associated comorbidities such as hypertension, diabetes, and chronic obstructive pulmonary disease. We map the evidentiary, conceptual, methodological, measurement, population, temporal, and translational gaps that currently limit clinical adoption of these markers, particularly in resource-constrained and under-represented settings such as India. Addressing these gaps through adequately powered, stage-specific, and longitudinal studies could establish affordable biomarker panels as scalable adjuncts to AHI for risk stratification and could inform decision-support pathways for respiratory therapists and clinicians managing OSA in low- and middle-income countries.

Read PDF

Similar papers

Open access Nov 2026

Hypoxic Burden Predicts Symptomatic but Not Sleep Architecture Response to CPAP Therapy in Obstructive Sleep Apnea

The apnea-hypopnea index (AHI) remains the standard metric for assessing obstructive sleep apnea (OSA) severity, although it does not fully capture the physiological consequences of respiratory events. Hypoxic burden (HB), which integrates the frequency, depth, and duration of oxygen desaturations, has been proposed as...

S. Baecker, F. Ehrlich, T. Sehr et al. · 0 citations
Review Open access Sep 2026

Beyond the Apnea-Hypopnea Index: Cardiovascular and Metabolic Phenotyping of Hypertensive Patients with Obstructive Sleep Apnea—A Narrative Review

Obstructive sleep apnea (OSA) is strongly associated with hypertension, yet the apnea–hypopnea index (AHI), while it defines the presence and frequency of respiratory events, predicts cardiovascular risk less reliably in the individual patient than metrics that incorporate the depth and duration of hypoxic exposure. Pa...

Georgiana-Mihaela Cebuc Simeanu, A. Glodeanu, Diana-Cristina Protasiewicz-Timofticiuc et al. · 0 citations
Open access Oct 2026

Multidimensional physiological burden of nocturnal respiratory events improves the prediction of cardiovascular mortality in obstructive sleep apnoea

Obstructive sleep apnoea (OSA) is a prevalent cardiovascular (CV) risk factor, yet the clinical reliance on the apnoea-hypopnoea index (AHI) is increasingly questioned. The AHI is a crude frequency count that ignores the physiological heterogeneity of respiratory events, such as their duration, intensity, and tem...

Z. Huang, Z. Liu, Q. Luo et al. · 0 citations
Open access Sep 2026

Respiratory-hypoxic burden and multimorbidity-related vulnerability are distinct dimensions of obstructive sleep apnea: A retrospective cohort analysis.

BACKGROUND Obstructive sleep apnea (OSA) is a heterogeneous disorder in which conventional apnea-hypopnea index (AHI)-based severity classification incompletely captures respiratory burden, nocturnal hypoxemia, obesity, and multimorbidity. Whether OSA severity is organized along distinct respiratory and multimorbidity-...

Giada Gironda, Giulia Sartori, A. Fantin et al. · 0 citations
Open access Sep 2026

Respiratory event duration reveals novel phenotypes beyond the apnea–hypopnea index in obstructive sleep apnea

Background Obstructive sleep apnea (OSA) is a heterogeneous disorder characterized by recurrent upper airway collapse during sleep. Although the apnea–hypopnea index (AHI) remains the cornerstone of OSA diagnosis and severity assessment, it primarily reflects the frequency of respiratory events and may not adequately c...

Mo Chen, Jing Yang, Yang Yang et al. · 0 citations
Open access Oct 2026

Nighttime Respiratory Disturbance and Hypoxemia Associated with Impaired Linear Growth in Children with Obstructive Sleep Apnea

Objectives Although obstructive sleep apnea (OSA) related hypoxia shows stronger associations with multiple complications than respiratory disturbance, its impact on linear growth, a major pediatric concern, remains unclear. This study investigates independent effects of hypoxia and respiratory disturbance on the heigh...

Yuan Shi, Zhao-Hua Chen, Xu-Jun Feng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.